Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1980 Jun;28(3):860-6.
doi: 10.1128/iai.28.3.860-866.1980.

Effect of Mycobacterium bovis BCG vaccination upon Mycobacterium lepraemurium infection

Effect of Mycobacterium bovis BCG vaccination upon Mycobacterium lepraemurium infection

M J Lefford et al. Infect Immun. 1980 Jun.

Abstract

Mice were infected with 10(8) Mycobacterium lepraemurium in the footpad (unsuppressed mice), and some of these animals were concurrently given 10(9) heat-killed M. lepraemurium intravenously (suppressed mice). These groups of mice were preimmunized with 10(7) viable organisms of Mycobacterium bovis BCG by several routes. BCG inhibited the proliferation of M. lepraemurium in the unsuppressed mice, but not in the suppressed mice. In effect, the intravenous administration of heat-killed M. lepraemurium suppressed the immunity to M. lepraemurium that BCG vaccination had engendered. BCG did not protect normal mice against intravenous infection with M. lepraemurium. It appears that normal mice against intravenous infection with M. lepraemurium. It appears that the inhibitory effect of BCG vaccination upon M. lepraemurium infection is due to cross-reactive immunity rather than to nonspecific immunity or immunopotentiation. Thus, the route of BCG vaccination was immaterial, and vaccination 12 weeks before M. lepraemurium infection was as beneficial as vaccination 4 weeks before infection. Moreover, spleen cells from M. lepraemurium-immunized mice conferred adoptive immunity to BCG. The implications of this study for the use of BCG as a prophylactic and therapeutic agent in human leprosy are discussed.

PubMed Disclaimer

References

    1. J Natl Cancer Inst. 1973 Nov;51(5):1669-76 - PubMed
    1. J Exp Med. 1964 Jul 1;120:105-20 - PubMed
    1. Int J Lepr. 1956 Jan-Mar;24(1):65-73 - PubMed
    1. Infect Immun. 1977 Dec;18(3):654-9 - PubMed
    1. Infect Immun. 1977 Nov;18(2):363-9 - PubMed

Publication types

LinkOut - more resources